近日,生物技术公司 Arvinas 在公布第一季度财报时,宣布了一系列重大调整举措。由于与辉瑞合作的雌激素受体(ER)降解剂研发数据喜忧参半,Arvinas 不仅终止了两项 3 期临床试验,还裁员 33% 以削减成本、延长资金使用周期。这一系列变动在生物医药领域引发广泛关注。试验数据不佳,终止两项 3 期试验今年 3 月,Arvinas 与辉瑞合作研发的靶向蛋白降解嵌合体(PROTAC)ER 降解...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.